PTSD Symptom Scale Interview (PSS-I)

Abstract

The PTSD Symptom Scale Interview (PSS-I) is a semi-structured clinician-administered diagnostic and severity instrument developed by Dr. Edna B. Foa and colleagues (Foa, Riggs, Dancu, & Rothbaum, 1993) to assess the presence and severity of posttraumatic stress disorder (PTSD) symptoms according to diagnostic criteria established in the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R and DSM-IV). Comprising 17 interviewer-administered items, the PSS-I evaluates three core symptom clusters: Re-experiencing (Items 1–5), Avoidance and Numbing (Items 6–12), and Increased Arousal (Items 13–17). Each item is rated on a 4-point Likert-type severity and frequency scale ranging from 0 (Not at all) to 3 (5 or more times per week / very much), yielding continuous total severity scores spanning from 0 to 51, as well as categorical diagnostic classifications based on DSM algorithmic scoring thresholds.

Psychometric evaluations across diverse trauma-exposed cohorts—including survivors of sexual assault, motor vehicle accidents, combat, and interpersonal violence—demonstrate excellent clinical properties. The instrument exhibits exceptional inter-rater reliability (overall diagnostic kappa κ = 0.91; intraclass correlation coefficients for continuous severity exceeding 0.90), robust internal consistency across subscales and total score (α = 0.85–0.92), and strong test-retest stability (r = 0.80). Construct and convergent validity are documented through high correlations with the Clinician-Administered PTSD Scale (CAPS; r = 0.87) and the Structured Clinical Interview for DSM (SCID), alongside demonstrated sensitivity to therapeutic changes following evidence-based trauma-focused interventions such as Prolonged Exposure (PE) therapy. This comprehensive review examines the theoretical foundations, latent factor structure, psychometric parameters, administration protocols, and clinical utility of the PSS-I.

Keywords

PTSD Symptom Scale Interview, PSS-I, posttraumatic stress disorder, clinical assessment, trauma psychometrics, Edna Foa, diagnostic semi-structured interview, re-experiencing, emotional numbing, hyperarousal

Authors

The PTSD Symptom Scale Interview was developed by a team of clinical psychologists and trauma researchers at the Center for the Treatment and Study of Anxiety (CTSA), Department of Psychiatry, University of Pennsylvania School of Medicine, and the Medical College of Pennsylvania:

• Edna B. Foa, Ph.D. — Professor of Clinical Psychology in Psychiatry and Director of the Center for the Treatment and Study of Anxiety, Perelman School of Medicine, University of Pennsylvania. Renowned for developing Prolonged Exposure therapy and foundational work in cognitive-behavioral paradigms for anxiety and trauma-related disorders. Correspondence: [email protected] / [email protected].
• David S. Riggs, Ph.D. — Clinical psychologist, research professor, and executive leader at the Center for Deployment Psychology, Uniformed Services University of the Health Sciences (USUHS), Bethesda, Maryland; former investigator at the Center for the Treatment and Study of Anxiety.
• Constance V. Dancu, Ph.D. — Clinical psychologist and researcher specializing in trauma recovery, sexual assault aftermath, and cognitive-behavioral protocols at the Medical College of Pennsylvania and the University of Pennsylvania.
• Barbara Olasov Rothbaum, Ph.D., ABPP — Professor of Psychiatry and Behavioral Sciences, Associate Vice Chair of Clinical Research, and Director of the Trauma and Anxiety Recovery Program at Emory University School of Medicine; pioneer in virtual reality exposure therapy and post-trauma psychopathology.

Purpose

The primary clinical and empirical objective of the PTSD Symptom Scale Interview (PSS-I) is to provide an efficient, rigorous, semi-structured assessment tool capable of both establishing a formal DSM-based categorical diagnosis of PTSD and quantifying the continuous dimensional severity of individual trauma symptoms over designated recall intervals (typically the past two weeks or past month). Prior to the emergence of the PSS-I and the Clinician-Administered PTSD Scale (CAPS), researchers and clinicians faced a methodological trade-off: lengthy diagnostic interviews (such as the SCID-PTSD module or the Diagnostic Interview Schedule) often required extensive clinical time and focused primarily on binary diagnostic thresholds, whereas self-report questionnaires (e.g., the Impact of Event Scale) lacked clinical probing, failed to authenticate whether reported symptoms directly stemmed from an index traumatic event, and risked inflated false-positive rates.

Foa and colleagues designed the PSS-I to overcome these operational constraints. By providing standardized clinical stems followed by systematic inquiry (“probe, then quantify”), the PSS-I equips clinicians to disentangle pre-existing general distress or comorbid depressive symptoms from genuine trauma-linked sequelae. The instrument serves multiple roles across clinical and research environments:

• Diagnostic Classification: Evaluating whether an individual satisfies the DSM symptom criteria: at least one intrusive re-experiencing symptom, at least three persistent avoidance and numbing symptoms, and at least two persistent increased arousal symptoms linked to a qualifying criterion-defined trauma.
• Dimensional Severity Monitoring: Generating granular continuous scores that reflect symptom intensity and frequency, enabling sensitive detection of treatment effects, symptom fluctuations, or natural recovery trajectories in longitudinal studies.
• Treatment Outcome Evaluation in Clinical Trials: Serving as a gold-standard primary outcome measure in randomized controlled trials (RCTs) assessing pharmacological agents (e.g., SSRIs) and psychotherapeutic interventions, particularly Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), and EMDR.
• Differential Diagnosis and Comorbidity Disentanglement: Distinguishing trauma-specific intrusions and avoidance patterns from generalized anxiety, panic disorder, major depressive disorder, and adjustment disorders through targeted behavioral anchoring.

Psychological Construct

The PSS-I operationalizes posttraumatic stress disorder as a multi-faceted clinical syndrome arising in the aftermath of exposure to an event involving actual or threatened death, serious injury, or violation of bodily integrity. The construct comprises three core symptomatic dimensions:

1. Re-experiencing / Intrusive Recolleciton (Items 1–5)

This dimension reflects the unbidden, spontaneous intrusion of traumatic memories into ongoing conscious awareness, reflecting a failure of normal memory integration and voluntary memory retrieval control. It includes:

• Recurrent intrusive distressing recollections (Item 1): Involuntary sensory fragments, thoughts, or images that hijack attention.
• Trauma-related nightmares and distressing dreams (Item 2): Recurrent sleep mentation depicting the traumatic event or capturing its emotional essence.
• Dissociative flashback episodes (Item 3): Severe episodes where the individual acts or feels as if the traumatic event were actively recurring in the present moment, accompanied by an attenuation of environmental orientation.
• Intense psychological reactivity to trauma reminders (Item 4): Acute emotional distress triggered by internal cues (e.g., somatic sensations) or external cues (e.g., smells, locations, dates, media).
• Intense physiological reactivity to trauma cues (Item 5): Autonomic nervous system hyperactivation (e.g., tachycardia, diaphoresis, tachypnea, peripheral vasoconstriction) upon exposure to conditioned trauma stimuli.

2. Avoidance and Numbing (Items 6–12)

This composite dimension captures both active behavioral and cognitive strategies designed to avert trauma-related distress, alongside widespread psychological constriction, emotional blunting, and social alienation:

• Active cognitive avoidance (Item 6): Deliberate, conscious efforts to suppress thoughts, conversations, or internal feelings associated with the index trauma.
• Active behavioral avoidance (Item 7): Avoidance of external triggers, including specific geographical locations, individuals, activities, or situations that stimulate traumatic memories.
• Psychogenic / trauma-related amnesia (Item 8): An inability to recall crucial aspects of the traumatic episode, unrelated to physical head trauma, alcohol intoxication, or neurological insult.
• Marked anhedonia (Item 9): Notable loss of interest or participation in previously rewarding activities, hobbies, or social pursuits.
• Interpersonal detachment and estrangement (Item 10): Feeling profoundly separated, isolated, or disconnected from family, peers, and social networks.
• Restricted affect / emotional numbing (Item 11): Inability to experience tender, joyful, or loving emotions, often accompanied by subjective emotional deadness.
• Foreshortened future (Item 12): A pervasive expectation of premature mortality, an inability to envision meaningful developmental milestones (such as marriage, career establishment, or parenthood), and a loss of long-range perspective.

3. Increased Arousal / Hyperarousal (Items 13–17)

This dimension encompasses persistent baseline neurobiological hyperarousal, sympathetic nervous system hyperactivity, and compromised inhibitory control over threat detection mechanisms:

• Sleep architecture disruption (Item 13): Persistent difficulties initiating or maintaining restorative sleep, characterized by initial insomnia, middle awakenings, or early-morning terminal awakening.
• Irritability and angry outbursts (Item 14): Disproportionate emotional lability, irritability, and episodes of verbal or behavioral aggression triggered by minimal provocation.
• Attentional and concentration impairment (Item 15): Severe difficulty sustaining cognitive focus, tracking conversations, reading, or executing occupational tasks.
• Hypervigilance (Item 16): Chronic, scanning alert state for potential danger or threat, involving defensive posture, seat positioning near exits, and chronic suspicion.
• Exaggerated startle response (Item 17): Heightened, prolonged somatic and motor responses to unexpected auditory, visual, or tactile stimuli.

Theoretical Framework

The PSS-I is grounded in Emotional Processing Theory (EPT), formulated by Edna B. Foa and Michael J. Kozak (1986) and further elaborated by Foa and Rothbaum (1998). EPT integrates concepts from cognitive-behavioral psychology, classical conditioning models, and bio-informational theories of emotional memory developed by Peter Lang.

According to Emotional Processing Theory, fear is represented in memory as a complex cognitive network or “fear structure” containing three distinct classes of information:

1. Information about the feared stimuli (e.g., dark alleyways, vehicle screeching, physical proximity of strangers, specific scents or vocal tones).
2. Information about fear responses (e.g., elevated heart rate, visceral panic, hyperventilation, impulse to escape, muscle tension).
3. Interpretive and meaning information associated with both stimuli and responses (e.g., “The world is entirely unsafe,” “People are universally malevolent,” “My rapid heart rate indicates I am dying,” “My symptoms prove I am permanently damaged”).

In individuals who develop PTSD, the trauma-related fear structure is uniquely pathological. It contains an overabundance of stimulus elements that have become inappropriately linked to catastrophic danger through stimulus generalization. Neutral environmental stimuli present during the traumatic event become conditioned fear stimuli. Furthermore, the meaning elements within the fear structure generate two pervasive pathogenic cognitive themes: (a) that the world is completely dangerous, and (b) that oneself is entirely incompetent, fragile, or permanently ruined.

The PSS-I’s tripartite structure maps onto the dynamics of this fear structure:

• Re-experiencing symptoms occur when internal or external environmental cues activate elements of the fear structure, causing the unintegrated sensory, physiological, and affective components of the trauma memory to flood conscious awareness.
• Avoidance and numbing behaviors represent functional defense mechanisms aimed at preventing the distressing activation of the fear network. In accordance with Mowrer’s Two-Factor Theory, avoidance is negatively reinforced through immediate short-term anxiety reduction. However, because avoidance prevents exposure to corrective information, the pathological fear structure remains unexamined and unresolved.
• Hyperarousal symptoms reflect chronic physiological sensitization, characterized by lowered thresholds for sympathetic nervous system firing and deficient prefrontal inhibition over amygdalar threat circuits.

Consequently, the PSS-I serves not only as a static descriptive checklist but also as a functional diagnostic map tracking the operational state of the client’s trauma-induced cognitive and physiological fear architecture.

Validity

Extensive empirical investigations have supported the construct, convergent, discriminant, and criterion-related validity of the PSS-I across civilian, forensic, and clinical populations.

Convergent and Criterion Validity

In their seminal validation study, Foa, Riggs, Dancu, and Rothbaum (1993) administered the PSS-I to a sample of 118 female assault survivors. Convergent validity was established by comparing PSS-I continuous severity scores with established measures of posttraumatic psychopathology and distress. The PSS-I total severity score demonstrated high correlation with the Impact of Event Scale (IES) (r = 0.80, p < .001), the Beck Depression Inventory (BDI) (r = 0.72, p < .001), and the State-Trait Anxiety Inventory (STAI) (State: r = 0.69; Trait: r = 0.73).

Foa and Tolin (2000) directly compared the PSS-I against the gold-standard Clinician-Administered PTSD Scale (CAPS) in a clinical cohort of trauma survivors. The correlation between the PSS-I total score and the CAPS total severity score was remarkably strong (r = 0.87, p < .0001). Subscale-to-subscale correlations between PSS-I and CAPS were similarly elevated: Re-experiencing (r = 0.82), Avoidance/Numbing (r = 0.81), and Hyperarousal (r = 0.78). Diagnostic agreement between PSS-I and CAPS yielded a Cohen’s kappa coefficient of κ = 0.82, confirming diagnostic equivalence.

Discriminant Validity

The PSS-I successfully distinguishes PTSD from comorbid psychological conditions. While correlations with general anxiety and depressive inventories are moderate to high (reflecting genuine affective comorbidity and general demoralization), receiver operating characteristic (ROC) analyses demonstrate that PSS-I total scores discriminate patients with PTSD from non-PTSD trauma-exposed survivors with high area under the curve (AUC > 0.90). Furthermore, specific subscales—particularly Re-experiencing and physiological reactivity—show negligible associations with measures of somatic concern unrelated to trauma, panic agoraphobia without trauma, or non-trauma-related social anxiety.

Treatment Sensitivity and Predictive Validity

The PSS-I displays robust sensitivity to clinical changes following psychotherapeutic interventions. Across numerous randomized clinical trials of Prolonged Exposure therapy, PSS-I scores decline in concordance with behavioral exposure milestones, demonstrating substantial effect sizes (Cohen’s d ranging from 1.2 to 2.1). In linguistic and biological trauma studies, such as those by Alvarez-Conrad, Foa, and Zoellner (2001), PSS-I severity scores significantly predicted physical health outcomes, somatic healthcare utilization, and trauma-narrative linguistic properties over 12-month follow-up intervals.

Reliability

The PSS-I exhibits strong reliability across multiple testing modalities, including internal consistency, inter-rater diagnostic concordance, and temporal stability.

Internal Consistency

Internal consistency coefficients (Cronbach’s alpha) documented across research programs confirm that the 17 items form a cohesive metric of posttraumatic stress:

• Total Scale Score: α = 0.85 to 0.92 across multiple civilian and clinical trials (Foa et al., 1993; Foa & Tolin, 2000).
• Re-experiencing Subscale: α = 0.78 to 0.85.
• Avoidance and Numbing Subscale: α = 0.80 to 0.86.
• Increased Arousal Subscale: α = 0.77 to 0.83.

Inter-Rater Reliability

Given that the PSS-I is an interviewer-administered instrument requiring clinical judgment, establishing inter-rater consensus is essential. In the primary psychometric validation study by Foa et al. (1993), pairs of trained clinical raters conducted concurrent ratings and blind audio-recorded assessments of trauma survivors:

• Diagnostic Agreement: The categorical determination of PTSD status (present vs. absent) yielded an inter-rater Cohen’s kappa of κ = 0.91 (p < .0001), indicating near-perfect agreement.
• Continuous Severity Agreement: Intraclass correlation coefficients (ICCs) for total symptom severity scores reached ICC = 0.97. Subscale intraclass correlations were likewise high: Re-experiencing (ICC = 0.93), Avoidance/Numbing (ICC = 0.96), and Increased Arousal (ICC = 0.94).

Test-Retest Stability

Temporal stability evaluated across short test-retest intervals (one to two weeks) in untreated, stable trauma populations showed high continuous score stability (Pearson r = 0.80 to 0.86), demonstrating that PSS-I scores reflect stable trait-like posttraumatic psychopathology rather than transient daily mood fluctuations.

Factor Analysis

The structural dimensionality of the 17 PSS-I items has been evaluated extensively via exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) across various theoretical models of posttraumatic stress disorder.

The Traditional DSM Tripartite Model

Initially, Foa et al. (1993) constructed the interview to mirror the tripartite DSM-III-R and DSM-IV diagnostic framework consisting of three correlated factors:

1. Intrusions / Re-experiencing (Items 1–5): Factor loadings typically range from 0.62 to 0.84, with Item 1 (intrusive thoughts) and Item 4 (emotional reactivity) exhibiting the strongest loadings.
2. Avoidance and Emotional Numbing (Items 6–12): Factor loadings range from 0.54 to 0.79, though Item 8 (trauma amnesia) often exhibits lower communality and cross-loadings.
3. Hyperarousal (Items 13–17): Factor loadings range from 0.58 to 0.81, led by Item 16 (hypervigilance) and Item 17 (startle reaction).

Alternative Latent Structures: 4-Factor Models

Subsequent psychometric investigations utilizing CFA on PSS-I data frequently demonstrated that the traditional three-factor model yielded adequate, but suboptimal, goodness-of-fit indices (e.g., Comparative Fit Index [CFI] ≈ 0.89; Root Mean Square Error of Approximation [RMSEA] ≈ 0.082). CFA investigations tested two competing four-factor structures:

• The King et al. (1998) Emotional Numbing Model: Divides the Avoidance/Numbing cluster into two separate latent factors: Effortful Avoidance (Items 6 and 7) and Emotional Numbing (Items 8, 9, 10, 11, and 12). When applied to PSS-I data, this four-factor model provides a significantly improved fit (χ²/df < 2.1, CFI = 0.95, TLI = 0.94, RMSEA = 0.051).
• The Simms et al. (2002) Dysphoria Model: Separates symptoms into Re-experiencing (Items 1–5), Avoidance (Items 6–7), Dysphoria (Items 8–15), and Hyperarousal (Items 16–17). The Dysphoria factor pools general emotional distress, sleep disruption, anger, and concentration difficulties, reflecting shared variance with major depressive and generalized anxiety disorders.

Empirical comparisons in clinical samples generally demonstrate that the King et al. emotional numbing model best captures the specific phenomenology measured by the PSS-I, confirming that active cognitive/behavioral avoidance is functionally distinct from passive emotional blunting and alienation.

Instrument / Measurement Tool

The PSS-I is administered as a clinician-led, semi-structured clinical interview. Key structural and administrative specifications include:

• Administration Time: Approximately 15 to 25 minutes, depending on the complexity of trauma history, spontaneous narrative detail, and participant cognitive processing speed.
• Interviewer Qualification: Administered by trained mental health professionals, clinical psychologists, psychiatrists, psychiatric nurses, or carefully trained graduate-level clinical researchers under supervisory review.
• Format: Semi-structured format wherein each item has a standardized stem question. Clinicians follow an explicit “probe, then quantify” rule: if the respondent endorses the symptom, the interviewer asks follow-up clarifying questions to establish symptom frequency (how many times per week) and clinical intensity (mild, moderate, or severe) within the reference timeframe.
• Recall Period: Standard clinical administration specifies the past two weeks or the past month.
• Item Count: 17 items mapped onto the 17 DSM-III-R / DSM-IV symptom criteria.
• Response Options & Anchor Weights:
  • 0 = Not at all
  • 1 = Once per week or less / a little
  • 2 = 2 to 4 times per week / somewhat
  • 3 = 5 or more times per week / very much
• Scoring and Diagnostic Rules:
  • Continuous Severity Score: Calculated by summing all 17 individual item ratings, yielding an overall score ranging from 0 to 51. Higher scores indicate greater PTSD symptom burden.
    • Re-experiencing Subscale Score: Sum of Items 1–5 (Range: 0–15).
    • Avoidance/Numbing Subscale Score: Sum of Items 6–12 (Range: 0–21).
    • Hyperarousal Subscale Score: Sum of Items 13–17 (Range: 0–15).
  • Categorical Diagnostic Algorithm: A symptom is counted as clinically present if endorsed with a rating of 1 or higher (or ≥ 2 in more conservative diagnostic protocols).
    • Criterion B (Re-experiencing): Requires endorsement of at least 1 symptom from Items 1–5.
    • Criterion C (Avoidance and Numbing): Requires endorsement of at least 3 symptoms from Items 6–12.
    • Criterion D (Increased Arousal): Requires endorsement of at least 2 symptoms from Items 13–17.
    • Final Diagnosis: Full diagnostic criteria are met if Criteria B, C, and D are satisfied, contingent upon confirmed exposure to an index traumatic stressor and accompanying functional impairment.

Permissions & Fee and Test Year

The original PTSD Symptom Scale Interview (PSS-I) was published in 1993 by Dr. Edna B. Foa and colleagues in Psychological Assessment. The instrument was developed with public and institutional research support to provide the clinical and scientific community with a standardized assessment tool.

• Permissions and Usage: The original PSS-I is broadly available for academic research, educational use, and non-commercial clinical practices. Researchers typically do not require payment of commercial per-administration license fees; however, proper academic citation of the foundational validation article (Foa et al., 1993) is required.
• Commercial and Proprietary Variations: Commercial clinical trials or corporate research programs seeking formatted manuals or updated DSM-5 editions (e.g., PSS-I-5) should request formal authorization from the developer or respective copyright holders. Inquiries regarding official interview protocols can be directed to the Center for the Treatment and Study of Anxiety (CTSA) at the University of Pennsylvania ([email protected]).

References

• Alvarez-Conrad, J., Foa, E. B., & Zoellner, L. A. (2001). Linguistic predictors of trauma pathology and physical health. Journal of Traumatic Stress, 14(4), 831–840. https://doi.org/10.1023/A:1013060205834
• Foa, E. B., & Kozak, M. J. (1986). Emotional processing of fear: Exposure to corrective information. Psychological Bulletin, 99(1), 20–35. https://doi.org/10.1037/0033-2909.99.1.20
• Foa, E. B., Riggs, D. S., Dancu, C. V., & Rothbaum, B. O. (1993). Reliability and validity of a brief instrument for assessing post-traumatic stress disorder. Psychological Assessment, 5(4), 459–467. https://doi.org/10.1037/1040-3590.5.4.459
• Foa, E. B., & Rothbaum, B. O. (1998). Treating the trauma of rape: Cognitive-behavioral therapy for PTSD. Guilford Press.
• Foa, E. B., & Tolin, D. F. (2000). Comparison of the PTSD Symptom Scale-Interview Version and the Clinician-Administered PTSD Scale. Journal of Traumatic Stress, 13(2), 181–191. https://doi.org/10.1023/A:1007781909213
• Hobfoll, S. E., Johnson, R. J., & Vranceanu, A.-M. (2007). Child multi-type maltreatment and associated depression and PTSD symptoms: The role of social support and stress. Journal of Consulting and Clinical Psychology, 75(6), 843–853. https://doi.org/10.1037/0022-006X.75.6.843
• King, D. W., Leskin, G. A., King, L. A., & Weathers, F. W. (1998). Confirmatory factor analysis of the Clinician-Administered PTSD Scale: Evidence for the dimensionality of posttraumatic stress disorder. Psychological Assessment, 10(2), 90–96. https://doi.org/10.1037/1040-3590.10.2.90
• Simms, L. J., Watson, D., & Doebbeling, B. N. (2002). Confirmatory factor analyses of posttraumatic stress symptoms in deployed and nondeployed veterans of the Gulf War. Journal of Abnormal Psychology, 111(4), 637–647. https://doi.org/10.1037/0021-843X.111.4.637

13. Items of the Scale (Questionnaire)